Effect of the novel NOD1 inhibitor GSK’217 on NOD1 and TLR4 ligand mediated CXCL8 release by HMVEC.

<p>CXCL8 release at 24 hours in HMVEC stimulated by iE-DAP 10 µg/ml (NOD1 agonist) or LPS 1 µg/ml (TLR4 agonist) following 30 minutes pre-treatment with the novel NOD1 antagonist GSK’217. Results are expressed as a percentage of response to the agonist alone (mean ± SEM; m = 6). Results were analysed by 1-sample t-test (*P<0.05) and by 2-way ANOVA (#P<0.05 <i>vs.</i> LPS).